Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB ... receiving pharmacologic treatment for BPH.

2, 2025 (HealthDay News) -- Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB) symptoms receiving pharmacologic therapy ... who are ...

One explanation for this is our inability to differentiate between symptoms attributable to detrusor overactivity (DO) and those caused by bladder ... treatment comprises men with urodynamic ...

(HealthDay News) — Gemtesa (vibegron) has been approved by the US Food and Drug Administration for men with overactive bladder (OAB) symptoms receiving pharmacologic therapy ... who are receiving ...

2, 2025 (HealthDay News) — Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB) symptoms receiving pharmacologic therapy ... who are ...

The standard treatments for overactive bladder include lifestyle changes, bladder training, pelvic floor muscle training and anticholinergic (anti-muscarinic) drugs. Additional treatments for some ...

An overactive bladder may be temporary or become a chronic condition. How long the symptoms last may depend on factors like the underlying cause and treatment adherence. Some conditions may cause ...

In women, causes of overactive bladder are varied, but the common consequence, beyond the physical manifestations, are frustration and embarrassment. While medications designed to relax the bladder ...

Urination problems affect millions of men worldwide, often developing so gradually that many dismiss early warning signs.